The Prognostic Significance of Metabolic Syndrome and a Related Six-IncRNA Signature in Esophageal Squamous Cell Carcinoma

Yu Liu¹, Liyu Wang¹, Hengchang Liu², Chunxiang Li¹* and Jie He¹*

¹ Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ² Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background: Metabolic syndrome (MetS) is associated with the development of esophageal squamous cell carcinoma (ESCC), and long non-coding RNAs (lncRNAs) are involved in a variety of mechanisms of MetS and tumor. This study will explore the prognostic effect of MetS and the associated IncRNA signature on ESCC.

Methods: Our previous RNA-chip data (GSE53624, GSE53622) for 179 ESCC patients were reanalyzed according to MetS. The recurrence-free survival (RFS) was collected for these patients. The status of the MetS-related tumor microenvironment was analyzed with the CIBERSORT and ESTIMATE algorithms. A lncRNA signature was established with univariate and multivariate Cox proportional hazards regression (PHR) analysis and verified using the Kaplan–Meier survival curve analysis and time-dependent receiver operating characteristic (ROC) curves. A clinical predictive model was constructed based on multiple risk factors, evaluated using C-indexes and calibration curves, and verified using data from the GEO and TCGA databases.

Results: The results showed that MetS was an independent risk factor for ESCC patients conferring low OS and RFS. Tumor microenvironment analysis indicated that patients with MetS have high stromal scores and M2 macrophage infiltration. A six-IncRNA signature was established by 60 ESCC patients randomly selected from GSE53624 and identified with an effective predictive ability in validation cohorts (59 patients from GSE53624 and 60 patients from GSE53622), subgroup analysis, and ESCC patients from TCGA. MetS and the six-IncRNA signature could be regarded as independent risk factors and enhanced predictive ability in the clinical predictive model.

Conclusions: Our results indicated that MetS was associated with poor prognosis in ESCC patients, and the possible mechanism was related to changes in the tumor microenvironment. MetS and the six-IncRNA signature could also serve as independent risk factors with available clinical application value.

Keywords: metabolic syndrome, IncRNA signature, prognosis, esophageal squamous cell carcinoma, clinical predictive model
INTRODUCTION

Metabolic syndrome (MetS) represents a cluster of metabolic disorders, including obesity, hyperglycemia, hypertension, and dyslipidemia. The prevalence of MetS remains stable in nearly 35% of all adults in the United States (1, 2). A recent study showed a high prevalence of MetS at 33.9% (31% in men and 36.8% in women), with a dramatic increase from 2000 to 2010 in China (3). MetS is an embodiment of comprehensive effects and is associated with multiple diseases, including tumors (4, 5). The presence of MetS can increase the risk and influence the prognosis of various tumors, such as colorectal cancer, breast cancer, and prostate cancer (6–8). The potential mechanisms mainly include obesity, chronic hyperinsulinemia, sustained inflammation-related signaling, estrogen signaling, and extracellular matrix remodeling (9, 10).

Esophageal cancer is the fourth most common cancer in China, with a 5-year survival rate of ~20%, because patients are often diagnosed at an advanced stage (11–13). Some studies have shown that obesity or MetS is associated with the risk and development of esophageal cancer (13–18). A prospective study of 2,396 esophageal squamous cell carcinoma (ESCC) patients demonstrated that MetS was a significant independent predictor of poor prognosis and was associated with glycolipid metabolism disorder (13). However, studies have also shown that MetS might be a good prognostic factor because of the good nutritional status of ESCC patients (15, 18).

Long non-coding RNAs (lncRNAs) are closely associated with tumor development and influence the prognosis of patients with tumors (19–21). The previous studies have indicated the predictive ability of lncRNA signatures for the prognosis of ESCC including our previous study (22–24). In addition, some studies also revealed that lncRNA was associated with the MetS or related metabolism disorder (25, 26). Considering the ambiguous relationship between MetS and survival of ESCC patients, we collected preoperative information of those 179 cases to identify a correlation. The relevant mechanism was explored with gene expression profiling, and a MetS-related lncRNA signature was established for predicting prognosis.

MATERIALS AND METHODS

The Reanalysis of ESCC Patient Clinical Data

In total, 179 patients were surgically confirmed to have ESCC at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences (CAMS) between 2005 and 2008. Preoperative clinical information about MetS, including preoperative body mass index, fasting blood glucose level, blood pressure, and triglyceride and high-density lipoprotein cholesterol levels, was collected. We defined MetS in our study according to the criteria of the Chinese Diabetes Society in 2004 as previous studies shown (13). Recurrence-free survival (RFS) was collected and defined as the interval from the data of surgery to the end of follow-up results or death.

The Selection of Esophageal Cancer and Related Cancer Databases

The microarrays or RNA-seq data were searched with keywords as esophagus/esophageal cancer or esophagus/esophageal carcinoma from public database. The inclusive criteria are as follows: (1) microarrays or RNA-seq database of ESCC and more than 10 patients’ tumor tissue; (2) available clinical information, accurate follow-up, and valuable prognostic information; and (3) the database includes the lncRNA expression profiles.

The expression profiles for 119 patients from GSE53624 and 60 patients from GSE53622 were generated using the Agilent human lncRNA+mRNA array V.2.0 platform. The 119 ESCC patients from GSE53624 were randomly divided into 60 ESCC and 59 ESCC patients by caret package of R (set.seed = 1,000, p = 0.50). We used the 60 ESCC patients as the training cohorts.
**TABLE 1** | The clinical characteristics at baseline, stratified by metabolic syndrome (MetS).

| Variable               | Without MetS | With MetS | \( p \) value |
|------------------------|--------------|-----------|---------------|
| No. of patients        | 153          | 26        |               |
| Age                    | 0.061        |           |               |
| <50                    | 21 (13.73%)  | 2 (7.69%) |               |
| 50-59                  | 60 (39.22%)  | 6 (23.08%)|               |
| 60-69                  | 58 (37.91%)  | 12 (46.15%)|             |
| 70-79                  | 11 (7.19%)   | 6 (23.08%)|               |
| >80                    | 3 (1.96%)    | 0 (0.00%) |               |
| Gender                 |              |           | 0.227         |
| Male                   | 127 (83.01%) | 19 (73.08%)|            |
| Female                 | 26 (16.99%)  | 7 (26.92%) |             |
| Tobacco use            |              |           | 0.116         |
| No                     | 52 (33.99%)  | 13 (50.00%)|              |
| Yes                    | 101 (66.01%) | 13 (50.00%)|             |
| Alcohol use            |              |           | 0.301         |
| No                     | 60 (39.22%)  | 13 (50.00%)|              |
| Yes                    | 93 (60.78%)  | 13 (50.00%)|             |
| Arrhythmia             |              |           | 0.903         |
| No                     | 116 (75.82%) | 20 (76.92%)|             |
| Yes                    | 37 (24.18%)  | 6 (23.08%) |             |
| Pneumonia              |              |           | 0.367         |
| No                     | 139 (90.85%) | 25 (96.15%)|              |
| Yes                    | 14 (9.15%)   | 1 (3.85%)  |             |
| Anastomotic leak       |              |           | 0.286         |
| No                     | 144 (94.12%) | 23 (88.46%)|              |
| Yes                    | 9 (5.88%)    | 3 (11.54%) |             |
| Adjuvant therapy       |              |           | 0.794         |
| No                     | 49 (32.03%)  | 9 (34.62%) |              |
| Yes                    | 104 (67.97%) | 17 (65.38%)|             |
| T stage                |              |           | 0.553         |
| T1                     | 10 (6.54%)   | 2 (7.69%)  |               |
| T2                     | 21 (13.73%)  | 6 (23.08%) |               |
| T3                     | 97 (63.40%)  | 13 (50.00%)|             |
| T4                     | 25 (16.34%)  | 5 (19.23%) |               |
| N stage                |              |           | 0.501         |
| N0                     | 70 (45.75%)  | 13 (50.00%)|               |
| N1                     | 53 (34.64%)  | 9 (34.62%) |               |
| N2                     | 18 (11.76%)  | 4 (15.38%) |               |
| N3                     | 12 (7.84%)   | 0 (0.00%)  |               |
| TNM stage              |              |           | 0.809         |
| I                      | 8 (5.23%)    | 2 (7.69%)  |               |
| II                     | 67 (43.79%)  | 10 (38.46%)|               |
| III                    | 78 (50.98%)  | 14 (53.85%)|             |
| Tumor location         |              |           | 0.142         |
| Upper                  | 19 (12.42%)  | 1 (3.85%)  |               |
| Middle                 | 85 (55.56%)  | 12 (46.15%)|             |
| Lower                  | 49 (32.03%)  | 13 (50.00%)|             |
| Tumor grade            |              |           | 0.066         |
| Well                   | 31 (20.26%)  | 1 (3.85%)  |               |
| Poorly                 | 43 (28.10%)  | 6 (23.08%) |               |
| Moderately             | 79 (51.63%)  | 19 (73.08%)|             |

(Continued)

**TABLE 1** | Continued

| Variable               | Without MetS | With MetS | \( p \) value |
|------------------------|--------------|-----------|---------------|
| Whether death          |              |           | 0.047*        |
| No                     | 67 (43.79%)  | 6 (23.08%)|               |
| Yes                    | 86 (66.21%)  | 20 (76.92%)|             |
| OS                     | 37.81 ± 23.01| 27.10 ± 20.00 | 0.027*       |
| Whether recurrence     |              |           | 0.071         |
| No                     | 88 (57.52%)  | 10 (38.46%)|             |
| Yes                    | 65 (42.48%)  | 16 (61.54%)|             |
| RFS                    | 30.58 ± 25.49| 20.20 ± 21.08 | 0.051       |

\(^* p < 0.05.\)

and 59 ESCC patients were used as the internal validation cohort. Another 60 ESCC patients from GSE53622 were used as an independent validation cohort (http://www.ncbi.nlm.nih.gov/geo) (22, 27). Meanwhile, the transcriptome expression profiles and corresponding clinical information of ESCC were downloaded from TCGA (https://tcga-data.nci.nih.gov/). All selected expression datasets were standardized before use.

**The Analysis of the Tumor Microenvironment by Immune Infiltration Profiles and Stromal Scores**

The tumor and adjacent normal tissues of 179 ESCC patients (GSE53624, GSE53622) were used for analysis. CIBERSORT is a deconvolution algorithm that uses a signature matrix of 547 genes to represent 22 types of infiltrating immune cells (28). CIBERSORT derives a \( p \) value for the deconvolution for each sample using Monte Carlo sampling, and samples with \( p > 0.05 \) are removed. The ESTIMATE algorithm (29) was used to calculate the immune and stromal scores for each tumor sample. These algorithms were used to analyze the clinical correlation among MetS status, T stage, N stage, TNM stage, tumor grade, and survival.

**Identification of IncRNA Signature to Predict the Prognosis for ESCC Patients**

Differences in mRNA and IncRNA expression (GSE53624, GSE53622) classified with MetS of 179 ESCC patients were screened by fold change > 1 and adj \( p < 0.05 \). Next, weighted gene co-expression network analysis (WGCNA) was also used to determine the relationship between the module gene and MetS. Significantly correlated module genes were selected using univariate Cox proportional hazards regression (PHR) analysis to calculate the correlation with OS and RFS. The identified IncRNAs with \( |z| > 2 \) were selected, and then, multivariate stepwise Cox PHR analysis was used to build a IncRNA predicting model and identify the best risk score cutoff value to distinguish ESCC patients. Kaplan–Meier survival curve analysis and log-rank tests were used to calculate differences between groups. Subsequently, time-dependent receiver operating characteristic (ROC) curves and areas under ROC curves (AUCs) were calculated to verify the reliability of our IncRNA signature.
Validation of the Six-lncRNA Signature

Validation sets of 59 cases from GSE53624 and 60 patients from GSE53622 were used to validate the predictive power of our lncRNA signature. A total of 179 patients and 80 patients from TCGA were all used for analysis. The caret package of R was used randomly divided 179 ESCC patients into two groups to verify the predictive power (set.seed = 1,000, p = 0.50). Subgroup analyses of 179 ESCC patients by tumor grade and TNM stage were also used to evaluate the predictive power. The detailed workflow is shown in Figure 9.

Functional Enrichment Analysis and Construction of a PPI Network

MetS-relevant module genes were selected by WGCNA and analyzed by DAVID (https://david.ncifcrf.gov/) (30). Meanwhile, a protein–protein interaction (PPI) network was constructed using the STRING database and Cytoscape software (31, 32). We selected the top 50 hub genes by cytoHubba and analyzed them using ClueGO in Cytoscape software.

The Clinical Predictive Model

The MetS, six-lncRNA signature and 179 ESCC patients’ risk factors were used to establish a clinical predictive model to analyze the application value. The performance of the nomogram was assessed using Harrel’s concordance indexes (C-indexes) and calibration curves. Bootstraps with 1000 resamples were used for these activities. We used the random group as internal validation and ESCC patients as an external validation group.

Statistical Analysis

Clinical statistical analysis was performed using EmpowerStats (http://www.empowerstats.com/). A p < 0.05 was considered statistically significant. Hazard ratios (HRs) and 95% confidence intervals (CIs) were also calculated. ActivePerl software (www.activestate.com/products/activeperl/) was used to extract and

### TABLE 2 | Association between metabolic syndrome (MetS) and overall survival (OS) in 179 patients in a univariate and multivariate analysis.

| Variable                      | Univariable |                           | Multivariable |                           |
|-------------------------------|-------------|----------------------------|---------------|----------------------------|
|                               | Hazard ratio| 95% confidence interval    | p             | Hazard ratio               | 95% confidence interval | p             |
| Age                           |             |                            |               |                           |                           |               |
| <50/50–59                     | 0.91        | 0.46–1.78                  | 0.776         | 1.48–2.06                 | 0.979                    |
| 60–69/50–59                   | 1.35        | 0.87–2.11                  | 0.185         | 0.88–2.35                 | 0.150                    |
| 70–79/50–59                   | 1.91        | 1.01–3.61                  | 0.047*        | 1.02–4.25                 | 0.044*                   |
| >80/50–59                     | 5.39        | 1.64–17.69                 | 0.005**       | 3.62–46.44                | 0.0001***                |
| Gender                        |             |                            |               |                           |                           |               |
| Female/male                   | 1.28        | 0.80–2.05                  | 0.306         | –                         | –                        |
| Tobacco use                   | Yes/no      | 0.75                       | 0.51–1.10     | 0.144                     | –                        |
| Alcohol use                   | Yes/no      | 0.86                       | 0.59–1.27     | 0.457                     | –                        |
| Adjuvant therapy              | Yes/no      | 1.93                       | 1.22–3.04     | 0.004**                   | 1.24                     | 0.74–2.10     | 0.413        |
| T stage                       |             |                            |               |                           |                           |               |
| T1/T3                         | 0.97        | 0.44–2.12                  | 0.935         | 1.40                      | 0.48–4.08                | 0.532        |
| T2/T3                         | 1.05        | 0.80–1.82                  | 0.870         | 1.26                      | 0.65–2.45                | 0.501        |
| T4/T3                         | 1.64        | 1.00–2.67                  | 0.048*        | 1.69                      | 0.93–3.08                | 0.083        |
| N stage                       |             |                            |               |                           |                           |               |
| N1/N0                         | 2.04        | 1.31–3.18                  | 0.001***      | 1.37                      | 0.68–2.75                | 0.379        |
| N2/N0                         | 2.05        | 1.14–3.70                  | 0.017*        | 1.20                      | 0.48–2.97                | 0.694        |
| N3/N0                         | 2.97        | 1.42–6.19                  | 0.003**       | 1.74                      | 0.65–4.64                | 0.270        |
| TNM stage                     |             |                            |               |                           |                           |               |
| T1/T2                         | 0.56        | 0.17–1.82                  | 0.336         | 0.55                      | 0.13–2.33                | 0.418        |
| T3/T2                         | 2.03        | 1.35–3.06                  | 0.0006***     | 1.68                      | 0.77–3.66                | 0.191        |
| Tumor location                |             |                            |               |                           |                           |               |
| Upper/middle                  | 1.47        | 0.83–2.59                  | 0.186         | 2.03                      | 1.07–3.86                | 0.029*       |
| Lower/middle                  | 0.88        | 0.57–1.35                  | 0.561         | 0.66                      | 0.41–1.07                | 0.088        |
| Tumor grade                   |             |                            |               |                           |                           |               |
| Well/moderately               | 0.99        | 0.57–1.70                  | 0.961         | 1.41                      | 0.75–2.66                | 0.287        |
| Poorly/moderately             | 1.63        | 1.06–2.50                  | 0.024*        | 1.68                      | 1.05–2.71                | 0.032*       |
| MetS                          |             |                            |               |                           |                           |               |
| With/without                  | 1.73        | 1.06–2.82                  | 0.027*        | 2.21                      | 1.27–3.86                | 0.005**      |
| BMI                           | Yes/no      | 1.30                       | 0.86–1.96     | 0.220                     | –                        | –             |
| Hyperglycemia                 | Yes/no      | 1.24                       | 0.83–1.83     | 0.294                     | –                        | –             |
| Hypertension                  | Yes/no      | 1.24                       | 0.83–1.84     | 0.290                     | –                        | –             |
| Triglycerides                 | Yes/no      | 1.11                       | 0.65–1.89     | 0.701                     | –                        | –             |
| HDL-C                         | Yes/no      | 0.95                       | 0.59–1.54     | 0.848                     | –                        | –             |
| LDL-C                         | Yes/no      | 1.07                       | 0.72–1.59     | 0.752                     | –                        | –             |
| Arrhythmia                    | Yes/no      | 1.12                       | 0.73–1.72     | 0.608                     | –                        | –             |
| Pneumonia                     | Yes/no      | 1.43                       | 0.72–2.83     | 0.309                     | –                        | –             |
| Anastomotic leak              | Yes/no      | 1.30                       | 0.60–2.80     | 0.503                     | –                        | –             |

*p < 0.05, **p < 0.01, ***p < 0.001.
We also found that age more than 70 years, high N stage, poor grade, and advanced TNM stage were significantly associated with worse OS. However, there was no apparent influence of single components of MetS, such as BMI, hyperglycemia, hypertension, and TG, HDL-C, and LDL-C levels. The multivariate Cox analysis demonstrated that MetS was an independent factor (HR = 2.21; 95% CI: 1.27–3.86; \( p = 0.005 \)). Meanwhile, age >70 years, poor grade, and upper tumor location were all identified as independent prognostic factors (Table 2).

We found that N stage, history of adjuvant therapy, hyperglycemia, T stage, and TNM stage were associated with RFS in univariate analysis, and MetS (HR = 1.71; 95% CI: 0.99–2.96; \( p = 0.0554 \)) influenced the RFS of patients. The multivariate Cox analysis demonstrated that adjuvant therapy (HR = 5.34; 95% CI: 2.23–12.77; \( p = 0.002 \)), TNM stage III (HR = 2.72; 95% CI: 1.12–6.61; \( p = 0.027 \)), and MetS (HR = 2.39; 95% CI: 1.29–4.43; \( p = 0.005 \)) were all significant risk factors (Table 3) for RFS.
MetS May Have an Effect on the Tumor Microenvironment

Mechanism-related gene sets of MetS were selected from MSigDB and analyzed within our groups (10, 33), and the results showed that differences in the expression of genes, such as IGF1, IGFALS, CSF1, TGFβ1, and TGFβ2, were associated with MetS (Figure 2A, Supplementary Table 1). Our module genes (MEgrey, MEsalmon, MEGreenyellow, and MEPurple) associated with MetS based on WGCNA were used to understand the molecular functions and pathways (Supplementary Figure 1). We found that extracellular matrix-related pathways were significantly enriched (Figure 2B). A PPI network of the top 50 hub genes and function enrichment were constructed and shown in Figures 2D,E. These results indicated that the effect of MetS on tumor prognosis might be associated with the tumor microenvironment.

Immune infiltration and stromal scores can reflect the status of the tumor microenvironment. Based on CIBERSORT, unmatched samples with \( p > 0.05 \) were removed, and a total of 139 normal and 155 tumor samples were used for further analysis. Our results showed that there were significant differences in the abundance of various immune cells (Figure 3A). Principal component analysis (PCA) could better distinguish normal and tumor tissues (Figure 3A), indicating a good predictive value.

We found that only naive CD4 T cells and M0 macrophages were associated with low RFS (Supplementary Figure 2A). Next, we explored the correlation between clinical features, such as T stage (gamma delta T cells, \( p < 0.05 \)), N stage (M1 macrophages and resting memory CD4 T cells, \( p < 0.05 \)), TNM stage (activated memory CD4 T cells and gamma delta T cells, \( p < 0.05 \)) and tumor grade (M0 macrophages, \( p < 0.05 \)), and different immune cells (Supplementary Figure 2B). Above all, the MetS group had a high infiltration of M2 macrophages (\( p = 0.04 \), Figure 3B), which display alternatively activated states with pro-tumorigenic effects. Meanwhile, the MetS group was significantly associated with the stromal scores based on the ESTIMATE algorithm (\( p = 0.006 \), Figure 3C).

Identification of a Six-lncRNA Signature

Four hundred sixty-six downregulated and 623 upregulated lncRNAs were found (Supplementary Figures 3A,B). \( z \) scores were calculated in the MetS-related four-lncRNA module (MEgrey, MEBLue, MEBrown, and METurquoise) with univariate Cox PHR analysis (Figure 4). A total of 42 lncRNAs were selected with \(|z| \) scores > 2 and \( p < 0.05 \). Finally, a six-lncRNA signature was established by multivariable stepwise Cox PHR analysis (Figure 5). The six-lncRNA signature was used to calculate risk scores using estimated regression coefficients to divide the 60 ESCC patients into a high-risk group (\( n = 33 \)) and a low-risk group (\( n = 27 \)) with a cutoff point of 1.051. There was a significant difference between the high- and low-risk groups.
in terms of OS ($p = 0.002$, Figure 6A) and RFS ($p = 0.003$, Figure 6B). Time-dependent ROC curves and areas under ROC curves (AUCs) for the six-lncRNA signature were determined and showed an effective predictive value at 3- and 5-year OS (0.785 and 0.786, respectively, Figure 6A) and RFS (0.795 and 0.783, respectively, Figure 6B). Finally, the six-lncRNA signature (AC005091.1, SNHG6, AC091544.4, DNAJB5-DT, HTT-AS, and ANKRD10-IT1) with the best prognostic performance was selected and the estimated regression coefficients are as follows:

Risk score = $(2.2544 \times \text{expression level of AC005091.1}) + (-5.1919 \times \text{expression level of SNHG6}) + (1.3410 \times \text{expression level of AC091544.4}) + (-1.3675 \times \text{expression level of DNAJB5-DT}) + (-4.0758 \times \text{expression level of HTT-AS}) + (3.6637 \times \text{expression level of ANKRD10-IT1})$.

Validation of the Six-lncRNA Signature

For verification, we found that the six-lncRNA signature could effectively distinguish the high- and low-risk groups in 59 patients from GSE53624 (OS: $p = 2.87E-05$; RFS: $p = 4.38E-05$, Figures 6C,D) and 60 patients from GSE53622 (OS: $p = 0.012$; RFS: $p = 0.05$, Figures 6E,F). The 80 ESCC patients from TCGA (OS: $p = 0.03$; RFS: $p = 0.05$, Supplementary Figure 4A), the 179 ESCC patients (OS: $p = 6.9E-09$; RFS: $p = 1.37e-07$, Supplementary Figure 4B), and randomly grouping all showed an effective predictive ability (Supplementary Figures 4C,D). In addition, we investigated the predictive power in subgroups based on TNM stage and tumor grade and identified a moderate performance for risk predicting (Figure 7).

The Six-lncRNA Signature Is an Independent Risk Factor

Multivariate Cox analysis demonstrated that the six-lncRNA signature could be regarded as an independent predictive factor for OS in the training and validation cohort (Table 4 and Supplementary Tables 2–4). A total of 179 patients demonstrated that the six-lncRNA signature could be regarded as an independent predictive factor for both OS (HR = 3.97; 95% CI: 2.47–6.36; $p = 0.0001$) and RFS (HR = 3.23; 95% CI: 1.95–5.35; $p = 0.0001$), as could be MetS for OS (HR = 2.67;
FIGURE 4 | The selection of lncRNA module using WGCNA. The merged dynamic of lncRNA module (A), network heatmap plot (B), four-module membership with gene significant (C) and the module trait relationship (D).

95% CI: 1.48–4.83; \( p = 0.001 \) and RFS (HR = 2.40; 95% CI: 1.25–4.60; \( p = 0.008 \), Table 4 and Supplementary Table 5). A total of 80 patients from TCGA demonstrated that the six-lncRNA signature was also an independent prognostic factor for OS (HR = 5.37; 95% CI: 1.02–28.41; \( p = 0.047 \)) and RFS (HR = 3.47; 95% CI: 1.04–11.62; \( p = 0.043 \), Table 4 and Supplementary Table 6).

Next, we selected MetS, lncRNA signature, age, tumor grade, TNM stage, and N stage to establish a prognostic nomogram to predict 3- and 5-year OS and RFS in 179 ESCC patients (Figures 8A,B). The C-index was 0.71 for OS and 0.75 for RFS (Figure 8C). Calibration curves for the nomogram for 3- and 5-year survival showed good agreement between the actual observation and prediction (Figures 8A,B). The lncRNA signature and MetS could all enhance the predictive power. Finally, the random group was used for internal validation. The ESCC patients with available clinical data from TCGA were classified into an external validation group. These results all showed a moderate predictive value (Figure 8D).

DISCUSSION

The prevalence of excess body weight and associated cancer burden have been increased over the past several decades globally (34). Nearly 30% of esophageal adenocarcinoma cases are attributable to excess body weight (body mass index, BMI \( \geq 25 \) kg/m\(^2\)) in 2012 worldwide (35). Obesity is considered an indicator of MetS and is associated with a high risk of esophageal carcinoma (16, 17). China has the highest incidence of esophageal cancer, especially ESCC, and the most important risk factors may be inadequate intake of fruits and vegetables, poor nutritional status, and drinking hot beverages and food (36, 37). Currently, based on population analysis, some studies (13, 15, 18) have indicated that MetS is associated with the prognosis of ESCC patients.

The effect of MetS on prognosis was largely mediated by single metabolic components such as hyperglycemia and dyslipidemia (13). Our study showed similar results but mainly reflected in the overall effect, not the single factor. The reason might be associated with the number and characteristics of the population.
These 179 ESCC patients with expression profiles allow us to explore the possible mechanisms from a molecular perspective and the detailed workflow is shown in Figure 9. The biological alterations associated with MetS that influence cancer development and the changes of related gene expression through high glucose, insulin resistance, abnormal cytokines or hormonal
level, chronic inflammation, and oxidative stress (9, 10). Insulin resistance-associated factors, such as IGF1 and IGFALS, and inflammation-related factors, such as CSF1 and TGFβ2, were all highly enriched in the MetS group (Figures 2A, C). We know that the high expression of IGF1 and inflammatory factors can promote tumor development by changing the tumor microenvironment (10, 38). The cytokines CSF1 and TGFβ have the ability to promote the transformation of M2 macrophages (39, 40). Immune infiltration analysis has also shown that the M2 macrophages were higher in the MetS group. The macrophages can be divided into three subtypes (M0, M1, and M2), where M0 is the unactivated subtype and can be differentiated into two M1 and M2 activated subtypes. M1 macrophages are pro-inflammatory and participate in the host innate immunity to kill tumor cells (41, 42). M2 macrophages are regarded as tumor-promotive and are correlated with poor prognosis in various cancers, including ESCC (43, 44). M2 macrophages could promote tumor metastasis by inducing epithelial–mesenchymal transition (EMT) or secreting cytokines such as IL-1β (45). The infiltrated immune cell can induce the host immune response to inhibit or promote the progression of tumor cells in the tumor microenvironment (42). Hence, the high infiltration rate of M2 macrophages in the MetS group might be associated with tumor microenvironment. Furthermore, the enrichment of ECM-related pathway and high stromal scores were also all found in the MetS group (Figures 2B, E, 3C). The extracellular matrix (ECM) regulated tissue development and homeostasis, and its dysregulation contributed to tumor progression (46). The ECM remodeling with secretion of fibronectin, collagens, and deposition of matrix proteins had an effect on the microenvironment during tumor progression (47–49). Above all, the change of tumor microenvironment in the MetS group might be the possible mechanism on tumor progression and a reason for the poor prognosis.

The recent studies have shown that immune cell infiltration could be used to establish a prognosis model in prostate cancer and colorectal cancer (42, 50). Hence, we also tried to establish a prognosis predictive signature based on immune infiltration profiles. Immune cell signature was established but with low predictive power (Supplementary Figures 5, 6). Then, we
constructed a lncRNA signature and found that the six-lncRNA signature had an available predictive ability for prognosis. The six-lncRNA signature was established with forward stepwise approach based on the 42 lncRNAs. Starting with the lncRNA “ANKRD10-IT1” with the largest univariate z score, we gradually added lncRNA and evaluated the prognostic performance. The process was repeated until no improvement can be found. Among the six-lncRNA signature components, SNHG6 has an effect on tumor progression in various cancer types, such as colorectal cancer (51), breast cancer (52), lung cancer (53), and ESCC (54). ANKRD10-IT1 was also regarded as a potential prognostic biomarker in hepatocellular carcinoma (55). The lncRNA signature and MetS were all associated with prognosis and could also serve as risk factor with available predictive ability (Figure 8). Next, we found that the combination use of immune infiltration signature only slightly enhances the predictive efficiency on prognosis (Supplementary Figure 5). These results indicated that the lncRNA signature might be appropriate to reflect the development of ESCC and have available predictive power. In total, our results indicated that MetS and multifunction lncRNA could be involved in the development of ESCC.

The previous studies all had the epidemiological perspective of exploring the relationship between MetS and ESCC (13, 15, 18). Our study is the first to explore the correlation from points of epidemiology and molecular mechanism and to successfully construct a six-lncRNA signature with a significant clinical application value. However, there are several limitations to our study. First, preoperative disease control status, pathogenic factors, and possible selection bias among patients with MetS

---

**FIGURE 8** | The establishment of the clinical predictive model. The prognostic nomogram was established by Age, Tumor grade, MetS, TNM stage, N stage, and lncRNA signature for OS (A) and RFS (B); the calibration curves for the nomogram for 3 and 5 years were also shown. The C-indexes were calculated and indicated that the six-lncRNA signature could enhance the predictive power in both training (C) and validation group (D).
CONCLUSIONS

Our results indicated that MetS was associated with poor prognosis in ESCC patients, and the possible mechanism was related to changes in the tumor microenvironment. MetS and the six-lncRNA signature could also serve as independent risk factors with clinical application value.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study come from the public free-charged database, and the new clinical information will be available from the corresponding author, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

All samples were collected with signed informed consent and were approved by Medical ethics committee of the Cancer institute and Hospital, Chinese Academy of Medical Sciences. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YL, CL, and JH: study design. YL, LW, and HL: data collections. YL: data analysis. YL, CL, and JH: writing. All authors reviewed the manuscript.

FUNDING

This work was supported by the Chinese National Natural Science Foundation (81972196), the National Key Basic Research Development Plan (2018YFC1312100, 2016YFC1303200), and the CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-1-005).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.00061/full#supplementary-material
REFERENCES

1. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. (2015) 13:1973–4. doi: 10.1001/jama.2015.4260
2. Shin D, Kongpaipaisarn K, Bohra C. Trends in the prevalence of metabolic syndrome and its components in the United States 2007–2014. Int J Cardiol. (2018) 5:216–9. doi: 10.1016/j.ijcard.2018.01.139
3. Lu J, Wang L, Li M, Xu Y, Jiang Y, Wang W, et al. Metabolic syndrome and weight loss in esophageal squamous cell carcinoma. Metabolism. (2018) 5:831–8. doi: 10.1016/j.metabol.2018.09.031
4. Lee JS, Cho SJ, Park HS. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol. (2010) 1:640–5. doi: 10.1093/annonc/mdp344
5. Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg. (2010) 2:509–63. doi: 10.1016/j.amjsurg.2009.05.005
6. Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res. (2013) 2:9. doi: 10.1186/1756-9966-32-9
7. Thomas GA, Alvarez-Reeves M, Lu L, Yu H, Irwin ML. Effect of exercise on metabolic syndrome and weight loss in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. (2014) 13:1973–30. doi: 10.1186/1756-9966-32-9
8. Peng F, Hu D, Lin X, Chen G, Liang B, Zhang H, et al. Analysis of long non-coding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome. Biomed Pharmacother. (2016) 8:101–9. doi: 10.1016/j.biopha.2016.01.001
9. He Q, Li JD, Huang W, Zhu WC, Yang JQ. Metabolic syndrome is associated with esophageal squamous cell carcinoma. Int J Cancer. (2018) 4:3655–69. doi: 10.1002/ijc.34338
10. Liu B, Cheng B, Wang C, Chen P, Cheng Y. The prognostic significance of metabolic syndrome and weight loss in esophageal squamous cell carcinoma. Sci Rep. (2018) 8:10101. doi: 10.1038/s41598-018-28268-2
11. Hauptman N, Glave D. Long non-coding RNA in cancer. Int J Mol Sci. (2013) 4:4655–69. doi: 10.3390/ijms14034655
12. Qu L, Wang ZL, Chen Q, Li YM, He HW, Hsieh JI, et al. Prognostic value of a long non-coding RNA signature in localized clear cell renal cell carcinoma. Eur Urol. (2018) 4:756–63. doi: 10.1016/j.eururo.2018.07.032
13. Li J, Wang W, Xia P, Wan L, Zhang L, Yu L, et al. Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer. Int J Cancer. (2018) 4:32150–60. doi: 10.1002/ijc.31573
14. Li, J; Chen Z, Tian L, Zhou C, He MY, Gao Y, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. (2014) 2:1700–10. doi: 10.1136/gutjnl-2013-305806
15. Mao Y, Fu Z, Zhang Y, Dong L, Zhang Y, Zhang Q, et al. A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma. Sci Rep. (2018) 8:8823. doi: 10.1038/s41598-018-27307-2
16. Huang GW, Xue YI, Wu ZY, Xu XE, Wu JY, Cao HH, et al. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma. BMC Cancer. (2018) 8:147. doi: 10.1186/s12885-018-4058-6
17. Liu HZ, Wang QY, Zhang Y, Qi DT, Li MW, Guo WQ, et al. Piglizatone up-regulates long non-coding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome. Biomed Pharmacother. (2016) 8:101–9. doi: 10.1016/j.biopha.2016.01.001
18. Lan X, Yan J, Ren J, Zong B, Li J, Li Y, et al. A novel long noncoding RNA Lnc-HC binds hnRNPA2B1 to regulate expression of Ptp7a and Abca1 in hepatocellular carcinoma metabolism. Hepatology. (2016) 4:58–72. doi: 10.1002/hep.28391
19. Barrett T, Wilhite SE, LEDoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. (2013) 1:4991–5. doi: 10.1093/nar/gkt1193
20. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. (2015) 2:453–7. doi: 10.1038/nmeth.3337
21. Yoshikawa K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. (2013) 4:2612. doi: 10.1038/ncomms3612
22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of molecular interaction networks. Genome Res. (2003) 3:2498–504. doi: 10.1101/gr.1239303
23. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. (2015) 3:3447–52. doi: 10.1093/nar/gku1003
24. Mendoza FM, de Sousa FR, Barbosa AL, Martins SC, Araujo RL, Soares R, et al. Metabolic syndrome and risk of cancer: which link? Metabolism. (2015) 4:482–9. doi: 10.1016/j.metabol.2014.10.008
25. Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Siegel CA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. (2019) 9:88–112. doi: 10.3322/caac.21499
26. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. (2018) 6:e66–e15. doi: 10.1016/S2213-8587(18)30150-5
27. Zou XW, Taylor PR, Mark SD, Chao A, Wang W, Dawsey SM, et al. Seasonal variation of food consumption and selected nutrient intake in Lanzian, a high risk area for esophageal cancer in China. Int J Vitam Nutr Res. (2003) 2:375–82. doi: 10.1024/0300-9831.72.6.375
28. Lang L, Lee AH, Xu F, Zhang T, Le J, Binns CW. Fruit and vegetable consumption and risk of esophageal cancer: a case-control study in north-west China. Dis Esophagus. (2014) 24:777–82. doi: 10.1111/dote.12157
29. Calle EE, Kaaks R, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. (2004) 4:579–91. doi: 10.1038/nrc1408
30. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapies. Immunol. (2011) 2:19–61. doi: 10.1016/j.muni.2014.06.010
31. Lampiasi N, Russo R, Zito F. The alternative faces of macrophage generate osteoclasts. Biomed Res Int. (2016) 16:9089610. doi: 10.1155/2016/9089610
32. Hume DA. The many alternative faces of macrophage activation. Front Immunol. (2015) 6:370. doi: 10.3389/fimmu.2015.00370
Ge P, Wang W, Li L, Zhang G, Gao Z, Tang Z, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of colorectal cancer. *Biomed Pharmacother.* (2019) 109:228. doi: 10.1016/j.biopha.2019.109228

Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. *Cancer Sci.* (2013) 4:1112–9. doi: 10.1111/cas.12188

Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. *Cancer Sci.* (2013) 4:1112–9. doi: 10.1111/cas.12188

Zhou J, Zheng S, Liu T, Liu Q, Chen Y, Tan D, et al. IL-1β from M2 macrophages promotes migration and invasion of ESCC cells enhancing epithelial-mesenchymal transition and activating NF-kB signaling pathway. *J Cell Biochem.* (2018) 19:7040–52. doi: 10.1002/jcb.26918

Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. *EMBO Rep.* (2014) 5:1243–53. doi: 10.15252/embr.201439246

Walker C, Mojares E, Del RHA. Role of extracellular matrix in development and cancer progression. *Int J Mol Sci.* (2018) 9:E3028. doi: 10.3390/ijms19103028

Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. *Trends Biotechnol.* (2015) 3:230–6. doi: 10.1016/j.tibtech.2015.01.004

Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Geffen A, et al. Tensional homeostasis and the malignant phenotype. *Cancer Cell.* (2005) 8:241–54. doi: 10.1016/j.ccr.2005.08.010

Meng J, Liu Y, Guan S, Fan S, Zhou J, Zhang M, et al. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. *Cancer Med.* (2019) 8:5202–13. doi: 10.1002/cam4.2433

Xu M, Chen X, Lin K, Zeng K, Liu X, Xu X, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a-5p in lung adenocarcinoma. *Biomed Pharmacother.* (2018) 109:228. doi: 10.1016/j.biopha.2018.08.099

Zhang Y, Li R, Ding X, Zhang K, Qin W. Upregulation of long non-coding RNA SNHG6 promote esophageal squamous cell carcinoma cell malignancy and its diagnostic value. *Am J Transl Res.* (2019) 1:1084–91.

Wang J, Pu J, Yao T, Lu X, Deng Y. Four long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma. *J Cell Physiol.* (2019) 34:8709–16. doi: 10.1002/jcp.27530

Yau MY, Xu L, Huang CL, Wong CM. Long non-coding RNAs in obesity-induced cancer. *Noncoding RNA.* (2018) 4:E19. doi: 10.3390/ncrna4030019

Chen D, Zhang Z, Mao C, Zhou Y, Yu L, Yin Y, et al. ANRIL inhibits p15INK4b through the TGFβ1 signaling pathway in human esophageal squamous cell carcinoma. *Cell Immunol.* (2014) 89:91–6. doi: 10.1016/j.cellimm.2014.03.015

Tan D, Wu Y, Hu L, He P, Xiong G, Bai Y, et al. Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. *Dis Esophagus.* (2017) 30:1–9. doi: 10.1111/dote.12481

Wang W, He X, Zheng Z, Ma X, Hu X, Wu D, et al. Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma. *Mol Cancer.* (2017) 6:75. doi: 10.1186/s12943-017-0643-6

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.